
Beijing's pilot allows companies to download and print approved import clearance documents digitally, reducing paperwork while maintaining existing regulatory requirements.

Indonesia extends halal certification deadlines for medicines, medical devices, cosmetics, and other regulated products, giving additional time to meet compliance requirements.

Learn how China’s proposed measures could affect market exclusivity for pediatric and rare disease drugs, including eligibility, filing timelines, and supply obligations.

China’s 2026–2030 pharmaceutical plan sets ambitious targets to turn its biopharma sector into a global innovation engine, reshaping international competition, licensing, and regulation.

Plan ahead for Malaysia NPRA’s 2026 year-end payment closure, featuring key deadlines for QUEST3+ online transactions and the Revenue Counter.

China’s latest policy sets new requirements for hospital medicine catalogs, prescribing practices, clinical evaluation, and performance-linked funding

BPJPH Regulation No. 4 of 2026 introduces pre-shipment halal verification and LPPH reports for imported goods starting September 2026.

Taiwan's TFDA has revised its processing time limits table for public applications, adding eight application items and amending two existing items.

China proposes ICH E6(R3) Annex 2 implementation from January 2027, with public comments open for one month from August 10 2026.

The guideline introduces more detailed evidence requirements for Hong Kong and Macao drug imports while retaining a streamlined pathway for products already approved under the GBA Connect scheme.

The draft clarifies when CDE may issue written supplementary information requests and when major deficiencies identified during review may instead lead to a non-approval conclusion.

The R&D import whitelist scheme streamlines customs clearance while maintaining specific eligibility, traceability, and risk-control requirements.
And discover how we can support you in getting your products certified for China.